Q3 2025 Earnings Call Transcript November 6, 2025 AstraZeneca PLC beats earnings expectations. Reported EPS is $1.19, ...

AstraZeneca is the biggest drugmaker in Britain and its £193 billion ($253 billion) market capitalization tops the London Stock Exchange.

Several pharmaceutical companies have said they will sell drugs directly to patients in the US and offer discounts ...

AstraZeneca (($AZN)) has held its Q3 earnings call. Read on for the main highlights of the call. AstraZeneca’s recent earnings call showcased a ...

AstraZeneca Pharma India reported a robust second quarter, with profit rising 41% year-on-year to ₹54.2 crore and revenue up 37%.

Eli Lilly and Novo Nordisk have agreed pricing deals for GLP-1RA brands, a pivotal moment in the obesity treatment market.

Under the model, set to start next year, the CMS will negotiate lower prices for Medicaid programs linked to those paid in ...

Known as GLP-1 receptor agonists, the drugs have soared in popularity in recent years, but patient access has been a ...

Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some ...

Positive full results from the NATRON Phase III trial showed AstraZeneca’s FASENRA (benralizumab) demonstrated a statistically significant delay in the time to first worsening or flare in ...

A single-inhaler triple therapy improved lung function in adults and adolescents with inadequately controlled asthma and was ...

Coverage of the drugs will expand to Medicare patients starting next year, and some lower prices will also be phased in for ...